Septerna (SEPN) Equity Ratio (2023 - 2026)

Septerna's quarterly Equity Ratio came in at 0.66 in Q1 2026, up 172.03% year-on-year from 0.24 in Q1 2025, and up 3.7% quarter-over-quarter from 0.64 in Q4 2025.

Septerna has reported Equity Ratio for 4 years, with the latest figure at 0.66 in Q1 2026.

  • For the quarter ending Q1 2026, Equity Ratio rose 172.03% year-over-year to 0.66; the trailing twelve-month figure through Mar 2026 stood at 0.66 (up 172.03% YoY), and the FY2025 full-year result was 0.64, down 30.37% from the prior year.
  • Equity Ratio for Q1 2026 stood at 0.66, up from 0.64 in the prior quarter.
  • The five-year high for Equity Ratio was 0.92 in Q4 2024, with the low at 0.92 in Q1 2025.
  • Average Equity Ratio over 4 years is 0.26, with a median of 0.64 recorded in 2025.
  • Year-over-year, Equity Ratio jumped 413.76% in 2024 and tumbled 30.37% in 2025.
  • Tracing SEPN's Equity Ratio over 4 years: stood at 0.29 in 2023, then jumped by 413.76% to 0.92 in 2024, then slumped by 30.37% to 0.64 in 2025, then climbed by 3.7% to 0.66 in 2026.
  • The last three Equity Ratio figures came in at 0.66 (Q1 2026), 0.64 (Q4 2025), and 0.64 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Ratio (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 0.04
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 0.42
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 0.73
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 0.77
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 0.21
10 Septerna 1.34 Bn 1.34 Bn - 0.66

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.66
Dec 31, 2025 0.64
Sep 30, 2025 0.64
Jun 30, 2025 0.91
Mar 31, 2025 -0.92
Dec 31, 2024 0.92
Sep 30, 2024 -0.50
Dec 31, 2023 -0.29